Journal Article Summary
The article examines the use of antithrombotic treatments in patients who are at high risk of bleeding after undergoing percutaneous coronary intervention (PCI). This topic is significant because patients with high bleeding risk (HBR) often face complications from standard antithrombotic therapies, which can lead to major bleeding events that are associated with increased mortality and morbidity. Understanding how to manage antithrombotic therapy in these patients is crucial for optimizing their care and minimizing risks.
The authors reviewed various strategies for antithrombotic therapy in patients with HBR following PCI. They found that shorter durations of dual antiplatelet therapy (DAPT) of 1 to 3 months, followed by single antiplatelet therapy, can reduce the risk of major bleeding without increasing the likelihood of adverse ischemic events. Additionally, de-escalating from more potent P2Y12 inhibitors to less potent options also showed promise in lowering bleeding risks. However, the research on long-term outcomes of these strategies remains limited.
Despite the promising findings, the article notes several limitations, including the need for more extensive studies to evaluate the long-term effects of shorter DAPT regimens. Patients and caregivers should be aware that while shorter DAPT may reduce bleeding risks, the potential for ischemic events still exists, particularly in complex cases. It is essential for individuals to discuss their specific risks and treatment options with their healthcare providers to ensure the best possible management of their antithrombotic therapy after PCI.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Almarzooq Zaid I., Al-Roub Nora M., Kinlay Scott. Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk. Current opinion in cardiology 2023. DOI: 10.1097/HCO.0000000000001075. PMID: 37522805. PMCID: PMC10592282.
Featured Pill Pals Product
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over --- Generic For Bayer Low Dose --- Time Cap Labs --- Over The Counter
1000 (1,000) Count Low Dose Aspirin 81mg for Adults and Children 12 years and over — Generic For Bayer Low Dose — Time Cap Labs — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
